Par Pharmaceutical Companies (PRX)
Par Pharmaceutical Companies Cash Flow
- Quarterly: March 2012 - December 2009 Previous Quarters
- Annual
| Cash Flow - Operations | 2012-03 | 2011-12 | 2011-09 | 2011-06 | 2011-03 | 2010-12 | 2010-09 | 2010-06 | 2010-03 | 2009-12 |
| Net Income | -28.72M | 51.84M | 21.93M | 9.054M | -108.97M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Depreciation, Depletion, Amortization | 13.58M | 10.04M | 5.613M | 6.139M | 6.242M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Other Non-Cash Items | 7.831M | -18.71M | 4.159M | 47.70M | -2.472M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Total Non-Cash Items | 21.41M | -8.67M | 9.772M | 53.84M | 3.77M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Deferred Income Taxes | -2.778M | 20.34M | 27.44M | -9.974M | -35.92M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Total Changes in Assets/Liabilities | 33.31M | 7.415M | -118.24M | -5.01M | 146.94M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Other Operating Activities | 0.386M | 0.516M | 0.268M | 0.252M | 0.262M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Net Cash from Operating Activities | 26.38M | 51.10M | -86.27M | 58.14M | 42.00M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Cash Flow - Investing | 2012-03 | 2011-12 | 2011-09 | 2011-06 | 2011-03 | 2010-12 | 2010-09 | 2010-06 | 2010-03 | 2009-12 |
| Capital Expenditures | -3.545M | -3.979M | -2.034M | -1.959M | -3.628M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Acquisitions, Divestitures | -24.69M | -412.75M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro | |||
| Investments | -4.066M | 4.973M | 7.384M | -10.60M | -0.811M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Other Investing Activities | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro | |||||
| Cash Flow - Financing | 2012-03 | 2011-12 | 2011-09 | 2011-06 | 2011-03 | 2010-12 | 2010-09 | 2010-06 | 2010-03 | 2009-12 |
| Net Cash from Investing Activities | -32.30M | -445.36M | 4.95M | -13.01M | -4.439M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Debt Issued | -4.375M | 345.62M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro | |||
| Equity Issued | 1.669M | -0.235M | -0.004M | 4.784M | -1.866M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Dividends Paid | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro | |||||
| Other Financing Activities | 2.98M | -14.59M | 0.279M | 0.924M | 1.802M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Net Cash from Financing Activities | 0.274M | 330.80M | 0.275M | 5.708M | -0.064M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Foreign Exchange Effects | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro | |||||
| Net Change in Cash & Cash Equivalents | -5.64M | -63.45M | -81.04M | 50.84M | 37.50M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Cash at beginning of period | 162.52M | 218.67M | 162.52M | 225.97M | 307.01M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
| Cash at end of period | 156.88M | 162.52M | 225.97M | 307.01M | 256.17M | Go Pro | Go Pro | Go Pro | Go Pro | Go Pro |
